CCI clears Torrent Pharma’s acquisition of JB Chemicals
ECONOMY & POLICY

CCI clears Torrent Pharma’s acquisition of JB Chemicals

The Competition Commission of India (CCI) has approved the proposed acquisition of J. B. Chemicals & Pharmaceuticals Limited by Torrent Pharmaceuticals Limited, subject to voluntary modifications offered by the parties.

The transaction involves Torrent Pharmaceuticals Limited (the acquirer) purchasing shareholding in J. B. Chemicals & Pharmaceuticals Limited (the target), followed by the amalgamation of the target company with the acquirer. Together, the two entities are referred to as the “parties”.

Torrent Pharmaceuticals, the flagship company of the Torrent Group, is engaged in the manufacture and sale of pharmaceutical formulations across multiple therapeutic segments.

J. B. Chemicals & Pharmaceuticals Limited operates in the manufacturing and marketing of a wide range of finished dosage formulations (FDFs) and active pharmaceutical ingredients (APIs). The company also provides Contract Development and Manufacturing Organisation (CDMO) services.

The CCI’s approval is conditional on the compliance of voluntary modifications proposed by both parties to address competition concerns.

A detailed order from the Commission will be issued in due course.

The Competition Commission of India (CCI) has approved the proposed acquisition of J. B. Chemicals & Pharmaceuticals Limited by Torrent Pharmaceuticals Limited, subject to voluntary modifications offered by the parties. The transaction involves Torrent Pharmaceuticals Limited (the acquirer) purchasing shareholding in J. B. Chemicals & Pharmaceuticals Limited (the target), followed by the amalgamation of the target company with the acquirer. Together, the two entities are referred to as the “parties”. Torrent Pharmaceuticals, the flagship company of the Torrent Group, is engaged in the manufacture and sale of pharmaceutical formulations across multiple therapeutic segments. J. B. Chemicals & Pharmaceuticals Limited operates in the manufacturing and marketing of a wide range of finished dosage formulations (FDFs) and active pharmaceutical ingredients (APIs). The company also provides Contract Development and Manufacturing Organisation (CDMO) services. The CCI’s approval is conditional on the compliance of voluntary modifications proposed by both parties to address competition concerns. A detailed order from the Commission will be issued in due course.

Related Stories

Gold Stories

Next Story
Infrastructure Energy

Asian Energy Services Q1 FY27 PAT Rises 129 Per Cent

Asian Energy Services Limited reported a 129 per cent year-on-year rise in net profit to Rs 128 million for Q1 FY27, compared with the corresponding quarter last year.Revenue increased 135 per cent year-on-year to Rs 2.71 billion, supported by continued momentum across its services business, disciplined execution and contributions from domestic and international operations. EBITDA grew 81 per cent year-on-year during the quarter.As of June 30, 2026, the company’s standalone order book stood at Rs 17.54 billion, with around 60 per cent coming from oil and gas services and 40 per cent from min..

Next Story
Infrastructure Urban

BioBTX to Build First Commercial-Scale Circular Chemicals Plant

Dutch circular chemistry technology developer BioBTX is building what it says will be the world’s first commercial-scale plant to convert mixed plastic waste into high-quality aromatic chemicals using its proprietary Integrated Catalytic Cracking Process (ICCP) technology.The facility will be built at Chemical Park Delfzijl on the northern coast of the Netherlands and is expected to create 35 jobs. Covestro, which has been a shareholder and strategic partner of BioBTX since 2024, holds a mid-single-digit million-euro investment in the company.BioBTX’s ICCP technology uses catalytic pyrolys..

Next Story
Real Estate

Awfis Q1 FY27 PAT Jumps 140% as Revenue Rises 27%

Awfis Space Solutions reported a 140 per cent year-on-year rise in consolidated profit after tax (PAT) to Rs 240 million for Q1 FY27, compared with Rs 100 million in the corresponding quarter last year.Revenue from operations increased 27 per cent to Rs 4.25 billion from Rs 3.35 billion, while EBITDA rose 28 per cent to Rs 1.62 billion. EBITDA margin improved to 38.2 per cent from 37.8 per cent. Profit before tax increased 135 per cent to Rs 240 million.The company's co-working business recorded 27 per cent year-on-year growth, supported by demand from enterprises, Global Capability Centres (G..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement